The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
M. G. Kris
Consultant or Advisory Role - ArQule; Boehringer Ingelheim; Chugai Pharma; Pfizer
B. E. Johnson
Other Remuneration - Genzyme; KEW Group
D. J. Kwiatkowski
No relevant relationships to disclose
A. J. Iafrate
No relevant relationships to disclose
I. I. Wistuba
No relevant relationships to disclose
S. L. Aronson
Other Remuneration - GeneInsight
J. A. Engelman
No relevant relationships to disclose
Y. Shyr
No relevant relationships to disclose
F. R. Khuri
No relevant relationships to disclose
C. M. Rudin
No relevant relationships to disclose
E. B. Garon
No relevant relationships to disclose
W. Pao
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MolecularMD; Symphony Evolution
Research Funding - AstraZeneca; Enzon; Xcovery
Other Remuneration - MolecularMD
J. H. Schiller
No relevant relationships to disclose
E. B. Haura
Research Funding - Pfizer
K. Shirai
No relevant relationships to disclose
G. Giaccone
No relevant relationships to disclose
L. D. Berry
No relevant relationships to disclose
K. Kugler
No relevant relationships to disclose
J. D. Minna
Research Funding - AstraZeneca; Geron
P. A. Bunn
No relevant relationships to disclose